Effect of osimertinib in ethnic Chinese with EGFR and T790M mutated NSCLC

Trial Identifier: D5160R00016
Sponsor:AstraZeneca
NCTID:NCT03133234
Start Date:May 2017
Primary Completion Date: September 2017
Study Completion Date: September 2017

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

CountryLocation
China Macau, China